Amgen Stock Sees Modest Gain Ahead of Pipeline Update

Amgen stock ended modestly higher on the Nasdaq at the close of September 15, 2026, with trading volume near its recent average. The move was in line with a weaker S&P 500, which also declined that day. This comes ahead of a pipeline-focused update highlighted in recent coverage.

At the close on September 15, 2026, Amgen stock finished modestly higher on the Nasdaq in USD terms, posting a small positive percent change for the session. The share price traded between an intraday low and an intraday high that bracketed the closing level, confirming a contained range for the day.

Amgen Inc.'s (ISIN US0311621009) September 15, 2026 close left it trading in the upper part of its observed band over the past year, underscoring that the stock remains well above its recent lows despite short-term swings. On the index side, the S&P 500 also closed lower on September 15, 2026, reflecting wider caution in US equities even as Amgen managed a modest gain.

Attention around Amgen today centers on its pipeline and growth priorities after a recent update highlighting programs such as the obesity candidate MariTide and the bispecific antibody IMDELLTRA. As trading resumes, broader US equity conditions remain relevant for Amgen, with recent market wraps pointing to pressure from higher government bond yields and rising oil prices.